5,724 Shares in Novartis AG $NVS Acquired by Mondrian Investment Partners LTD

Mondrian Investment Partners LTD bought a new stake in Novartis AG (NYSE:NVS) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 5,724 shares of the company’s stock, valued at approximately $734,000.

A number of other large investors also recently bought and sold shares of NVS. Brighton Jones LLC grew its stake in shares of Novartis by 76.5% during the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock valued at $599,000 after buying an additional 2,666 shares during the period. AQR Capital Management LLC raised its position in shares of Novartis by 102.8% in the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock worth $2,516,000 after buying an additional 11,444 shares during the period. Empowered Funds LLC acquired a new position in Novartis in the first quarter valued at $1,764,000. Sivia Capital Partners LLC grew its position in Novartis by 48.0% during the second quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock valued at $963,000 after acquiring an additional 2,581 shares during the period. Finally, TD Asset Management Inc increased its stake in Novartis by 18.8% during the second quarter. TD Asset Management Inc now owns 20,700 shares of the company’s stock worth $2,505,000 after acquiring an additional 3,271 shares during the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Stock Performance

Novartis stock opened at $163.09 on Tuesday. Novartis AG has a 12-month low of $97.71 and a 12-month high of $163.42. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.12 and a quick ratio of 0.89. The company has a market capitalization of $344.52 billion, a price-to-earnings ratio of 22.78, a price-to-earnings-growth ratio of 2.45 and a beta of 0.50. The firm’s fifty day moving average price is $144.17 and its 200 day moving average price is $132.86.

Novartis (NYSE:NVS) last announced its earnings results on Wednesday, February 4th. The company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.04. Novartis had a return on equity of 40.53% and a net margin of 25.65%.The company had revenue of $524.00 million during the quarter, compared to the consensus estimate of $13.85 billion. During the same period last year, the firm earned $1.98 earnings per share. The company’s revenue was up 1.4% on a year-over-year basis. On average, research analysts forecast that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Announces Dividend

The firm also recently disclosed an annual dividend, which will be paid on Monday, March 16th. Shareholders of record on Wednesday, March 11th will be issued a dividend of $4.773 per share. The ex-dividend date is Wednesday, March 11th. This represents a yield of 312.0%. Novartis’s payout ratio is currently 36.31%.

Analyst Ratings Changes

Several research firms have recently weighed in on NVS. Jefferies Financial Group reaffirmed a “hold” rating on shares of Novartis in a research note on Monday, October 27th. HC Wainwright lowered shares of Novartis to a “neutral” rating in a report on Monday, October 27th. Bank of America raised shares of Novartis from a “neutral” rating to a “buy” rating in a research report on Tuesday, November 25th. Cfra set a $126.00 price objective on shares of Novartis and gave the stock a “hold” rating in a research report on Wednesday, October 29th. Finally, JPMorgan Chase & Co. raised Novartis from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $119.75.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.